MTOR and renal cell carcinoma: Concordantly, inhibition of signal transduction pathways with receptor tyrosine kinase inhibitors, such as cabozantinib, or mTOR inhibitors, such as everolimus, have been associated with antitumor activity in a number of cancer types, including RCC [26, 27].